Understanding GLP-1 and MTHFR Gene Variance
- Dr. Amy Neuzil, Methylation and MTHFR Expert
- 4 hours ago
- 5 min read
GLP-1 inhibitors have gained attention in recent years for their role in managing blood sugar levels and supporting weight loss. But what exactly is GLP-1, how do these inhibitors work in the body, and what happens when they interact with genetic factors like the MTHFR gene variance? This article breaks down these questions with clear explanations and insights from peer-reviewed research.
What is GLP-1 and What Role Does It Play in the Body?
GLP-1 stands for glucagon-like peptide-1, a hormone produced in the gut after eating. It plays several important roles in regulating blood sugar and appetite:
Stimulates insulin secretion when blood sugar rises, helping cells absorb glucose.
Suppresses glucagon release, a hormone that raises blood sugar.
Slows gastric emptying, which helps control how quickly sugar enters the bloodstream.
Reduces appetite by acting on brain centers that regulate hunger.
GLP-1 is part of the body's natural system to maintain blood sugar balance, especially after meals. Its effects make it a target for diabetes and obesity treatments.
How GLP-1 Inhibitors Work
The term "GLP-1 inhibitors" is commonly used, but it's inaccurate and can be confusing because these drugs do not block GLP-1. Instead, these drugs are actually GLP-1 receptor agonists, but that is much harder to say and remember. Essentially, they function as GLP-1 analogs, mimicking the action of GLP-1 in the body. These medications mimic the action of natural GLP-1 by binding to and activating its receptor.
By doing this, they:
Increase insulin release in response to high blood sugar.
Decrease glucagon secretion.
Slow digestion to reduce blood sugar spikes.
Help reduce appetite and promote weight loss.
Common examples include liraglutide and semaglutide, which have been approved for type 2 diabetes and obesity management. Clinical trials show these drugs improve blood sugar control and support significant weight loss in many patients (Marso et al., 2016; Wilding et al., 2021).
The MTHFR Gene and Its Variance
The MTHFR gene encodes an enzyme called methylenetetrahydrofolate reductase, which is crucial for processing folate and regulating homocysteine levels in the blood. Variants in this gene, such as C677T and A1298C, can reduce enzyme activity and affect methylation processes.
People with MTHFR gene variants may experience:
Higher homocysteine levels, linked to cardiovascular risk.
Altered folate metabolism impacts DNA synthesis and repair.
Potential differences in drug metabolism and nutrient needs.
Higher tendency toward type 2 diabetes, (Pathak et. al., 2022), insulin resistance, and metabolic dysfunction, including normal weight obesity (De Lorenzo et al., 2025). These conditions may all be improved with GLP-1 receptor agonists.
How GLP-1 Inhibitors Might Interact with MTHFR Gene Variance
Research directly linking GLP-1 receptor agonists and MTHFR gene variants has not been performed yet. However, some considerations arise from understanding their biological roles:
Metabolic effects: Both GLP-1 activity and MTHFR function influence metabolism. MTHFR variants have been shown to alter response to blood sugars, increasing the risk for conditions including type 2 diabetes, insulin resistance, metabolic syndrome, and normal weight obesity. These are all good indications for GLP-1 receptor agonists with medical supervision.
Cardiovascular health: GLP-1 receptor agonists demonstrate cardiovascular benefits, including lowering blood pressure and improving lipid profiles. Since MTHFR variants can increase cardiovascular risk via both elevated homocysteine and altered glucose metabolism, GLP-1 drugs might offer complementary benefits.
Nutrient interactions: Folate metabolism, affected by MTHFR variants, could influence the effectiveness or side effects of GLP-1 drugs, especially if nutrient deficiencies are present. Blood testing for folate, homocysteine, and vitamin B12 is a good idea before starting therapy with GLP-1 receptor agonists.
Liver health: One compelling study (Werge et al. 2025) of people with metabolic dysfunction associated with steatotic liver disease (MASLD), which is an inflamed fatty liver linked to both poor blood sugar processing and dysfunctional methylation (in this paper, methylation is referred to as one-carbon metabolism). In this study, patients receiving the GLP-1 inhibitor showed benefits for their livers, as well as changes in folate, glycine, vitamin B6, betaine, and serine. This suggests that not only did the GLP-1 improve their metabolic profile, but it also improved their methylation.
More studies are needed to clarify these interactions. For now, patients with MTHFR variants should discuss their genetic background with healthcare providers when considering GLP-1 therapies.
Practical Tips for Patients and Providers
Genetic testing: Knowing MTHFR status can help personalize treatment plans, especially for those with metabolic or cardiovascular concerns.
Monitor nutrient levels: Folate, homocysteine, and vitamin B-12 status should be checked and optimized to support methylation and overall health.
Watch for side effects: GLP-1 receptor agonists can cause nausea or digestive discomfort; these effects may be influenced by individual genetic factors, although current research is limited in this area.
Lifestyle support: Combining medication with diet and exercise improves outcomes for everyone for blood sugar and weight management, but this is especially important for people with the MTHFR gene mutation.
Summary
GLP-1 receptor agonists work by mimicking a natural hormone that regulates blood sugar and appetite, making them effective for diabetes and obesity treatment. The MTHFR gene influences important metabolic pathways, and its variants may affect how individuals respond to these drugs. While direct evidence of interaction is limited, understanding both factors can help tailor treatment and improve health outcomes.
If you are considering GLP-1 therapy and have concerns about genetic factors like MTHFR, consult your healthcare provider for personalized advice.
References
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311-322. https://doi.org/10.1056/NEJMoa1603827
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
Bailey, L. B., & Gregory, J. F. (1999). Folate metabolism and requirements. The Journal of Nutrition, 129(4), 779-782. https://doi.org/10.1093/jn/129.4.779
Frosst, P., Blom, H. J., Milos, R., et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics, 10(1), 111-113. https://doi.org/10.1038/ng0595-111
De Lorenzo A, Gualtieri P, Frank G, Palma R, Cianci R, Romano L, Ciancarella L, Raffaelli G, Di Renzo L. Normal Weight Obesity Overview and Update: A narrative review. Current Obesity Reports. 2025 May 30;14(1):50. doi: 10.1007/s13679-025-00641-z. PMID: 40447890.
Pathak D, Shrivastav D, Verma AK, Alsayegh AA, Yadav P, Khan NH, Al-Harbi AI, Khan MI, Bihade K, Singh DD, Beg MMA. Role of metabolizing MTHFR gene polymorphism (rs1801133) and its mRNA expression among Type 2 Diabetes. Journal of Diabetes and Metabolic Disorders. 2022 Feb 19;21(1):511-516. doi: 10.1007/s40200-022-01001-7. PMID: 35673506; PMCID: PMC9167251.
Werge MP, McCann A, Rashu EB, Lam SM, Hetland LE, Thing M, Nabilou P, Junker AE, Norlin J, Veidal S, Holst D, Bugge A, Viuff BM, Hvid H, Bendtsen KM, Mazzoni G, Harder LM, Vyberg M, Serizawa R, Bendtsen F, Ueland PM, Galsgaard ED, Wewer Albrechtsen NJ, Gluud LL. Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide. Annals of Hepatology. 2025 Jul-Dec;30(2):102107. doi: 10.1016/j.aohep.2025.102107. Epub 2025 Aug 30. PMID: 40889707.
Comments